[DOI] [PubMed] [Google Scholar] 144.Lv L, et al
Maintenance therapy usually involves injections every two to three months
In individuals with congenital hyperinsulinism due to inactivating mutations in the genes encoding the beta cell K ATP channels, the GLP-1 receptor antagonist, exendin-(9-39), increases fasting plasma glucose and prevents protein-induced hypoglycemia
After three months of weekly injections, most patients either (a) reach their goal weight and transition off, or (b) benefit more from adjusting their dietary macros or adding structured cardio than from continuing injections
It crosses the blood-brain barrier to aid neurotransmitter production, supporting cognitive function and mood
Do not use on cuts, wounds, or other open areas of skin